Top Pharmaceutical Companies in Bangalore (43)

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Revenue Growth: Company-reported results indicate 34% year-over-year software growth in 2024, alongside earlier periods of 100% YoY elluminate software growth in 2022 and 50% in 2021. These signals point to sustained momentum in the software business.

Market Expansion: The organization added 20 net-new clients in 2024 and more than 20 in 2025, with its footprint among top global pharma expanding from 16 to 18 of the world’s top 50 companies. This reflects a widening customer base across large enterprise accounts.

Investor Backing & Capital Strength: A September 2024 majority investment by GI Partners—described as a growth investment—with previous investor Summit Partners retaining a minority stake indicates strong institutional support. Subsequent expansion of the executive team aligns with funding to drive the next phase of growth.

Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.

Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.

Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.

Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.

Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.

Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.

Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.

Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.

Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.

Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.

Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.

Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.

Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.

Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.

Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.

Strong Market Position & Advantage: Feedback suggests Parexel is consistently viewed as a top-tier, full-service CRO, reinforced by repeated industry awards and strong site collaboration recognition. These signals indicate competitive strength in winning and delivering complex global programs.

Strategic Partnerships: Feedback suggests multi-year collaborations to embed advanced analytics and AI (e.g., Palantir and other AI initiatives) are intended to improve trial efficiency and differentiation. Such partnerships underscore continued investment in modernization and execution.

Market Expansion: Feedback suggests the company opened a new global headquarters in Raleigh and continues to reference a 20,000+ to 24,000+ global workforce, indicating operational scaling. Physical expansion and ongoing hiring activity support broader delivery capacity across regions.

Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.

Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.

Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.

Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.

Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.

Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.

Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.

Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.

Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.

Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.

Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.

Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.